Thames Ventures VCT 2 PLC Reports Latest Net Asset Values
Recent Net Asset Values from Thames Ventures VCT 2 PLC
THAMES VENTURES VCT 2 PLC
LEI: 21380035MV1VRYEXPR95
Thames Ventures VCT 2 plc is pleased to share its latest unaudited Net Asset Values as of 30 June 2024. This report provides valuable insights into the financial performance of its various share classes.
Detailed Share Class Values
The following are the Net Asset Values for the different share classes:
Share Class Breakdown
1. Ventures Ordinary Share: 46.1p
2. Healthcare Ordinary Share: 40.9p
3. AIM Shares: 103.1p
4. DP67 Ordinary Share: 27.3p
These values reflect the ongoing commitment of Thames Ventures VCT 2 plc to deliver robust financial returns to its shareholders.
Understanding Net Asset Values
Net Asset Value (NAV) is a critical measure for assessing the valuation of a company’s shares. It represents the company's total assets minus its liabilities, providing investors with a clear picture of the company's worth. The NAV can fluctuate based on market conditions and the performance of the underlying assets.
The Importance of NAV in Investment Decisions
Investors often use NAV as a benchmark to make informed decisions about their investments. A higher NAV may indicate a more valuable investment, while a lower NAV might raise concerns about a company’s financial health. Thus, keeping track of NAV trends is crucial for long-term investment strategies.
Contact Information for Investors
For detailed information regarding investments, share classes, or financial queries, please reach out to the relevant representatives at Foresight Group LLP:
Company Secretary
Stephen Thayer
Tel: 0203 667 8100
Investor Relations
Andrew James
Tel: 0203 667 8181
Frequently Asked Questions
What is Net Asset Value (NAV)?
Net Asset Value (NAV) represents the difference between a company's total assets and its total liabilities, indicating its value per share.
When were the latest NAVs reported?
The latest unaudited Net Asset Values were reported as of 30 June 2024.
What are the NAVs for the different share classes?
The NAVs are 46.1p for Ventures Ordinary Share, 40.9p for Healthcare Ordinary Share, 103.1p for AIM Shares, and 27.3p for DP67 Ordinary Share.
Who can I contact for more information?
You can contact Stephen Thayer or Andrew James at Foresight Group LLP for inquiries regarding investments.
Why is monitoring NAV important for investors?
Monitoring NAV helps investors assess the valuation and performance of their investments, guiding their investment decisions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Cue Biopharma Sets $12 Million Public Offering to Fund Growth
- Microsoft's Bold $2.7B Investment to Transform Brazil's AI Landscape
- TRIBIT Launches Powerful StormBox Blast 2 Bluetooth Speaker
- Caldwell Cassady & Curry Secures $22.4M Patent Victory for SVV
- TRIBIT Unveils StormBox Blast 2: A 200W Bluetooth Revolution
- Join the Class Action Against Late Stage Asset Management
- United Atlantic Ventures Liquidates Large Stake in Trump Media
- Accruit Private Client Group Honors 2025 Best Lawyers for Real Estate
- Tokyo's Core CPI Observes a Stable 2.0% Increase Annually
- Morris Industries' Nate Morris Inspires at CEO Summit 2024
Recent Articles
- NASA and SpaceX Reschedule Crew-9 Mission Amid Weather Concerns
- Seth Farbman Takes the Stage at Lytham Partners' Conference
- Brink’s and Sainsbury’s Forge Partnership to Enhance ATM Services
- OncoC4 and AcroImmune Merger: A Milestone in Immunotherapy
- AGF Management Limited's Impressive Growth in Q3 Results
- Microbix Biosystems Inc. Showcases Innovations at Investor Event
- Abiologics Welcomes New Chief Scientific Officer to Propel Innovation
- AGF Management Limited Announces Q3 2024 Dividend of 11.5 Cents
- Atavistik Bio Welcomes Dr. Mohammad Hirmand to Leadership Team
- Southern Michigan Bancorp Announces Dividend and Future Plans
- Dr. Kira Espiritu Takes Charge as Dean at ACM-IAU
- Upcoming Highlights of the Emerging Growth Conference 2024
- Steakholder Foods' Agreement with Bondor Foods: A New Era for Plant-Based Innovations
- VersaBank Moves to Redeem Series 1 Preferred Shares Successfully
- Altair and Aston Martin Team Up for Eco-Friendly Vehicle Innovation
- Investigation Launched Against Extreme Networks for Fraud Allegations
- Accenture Set to Announce Q4 Results Amid Analyst Adjustments
- Septerna Accelerates Drug Development with Strategic Appointments
- Taylor Morrison Sets Earnings Release Date for Q3 2024
- Vertex Energy Secures $80M Financing Amid Bankruptcy Filing
- CULT Food Science's Noochies! Sprinkles: A Pet Nutrition Breakthrough
- FuelPositive Outlines Key Milestones for Green Ammonia Project
- Berkshire Hathaway's Strategic Move: Recent BofA Share Sales
- Global Payments Faces Analyst Pressure: Future Growth Uncertain
- UniCredit's Bold Strategy Sparks German Regulatory Concerns
- Kamala Harris Expands Support Against Trump Ahead of Election
- Long-Term Efficacy of BIMZELX in Plaque Psoriasis Patients
- Navigating Change: Southwest Airlines' Outlook and Plans
- Astralis Partners with GoWish to Revolutionize Fan Engagement
- Ribbon Communications: Analyzing Growth Prospects and Challenges
- Thermon Group Enhances Leadership to Drive Future Growth
- Finastra Welcomes Andrew Bateman to Boost Lending Sector Growth
- Kymera Therapeutics Advances KT-621: A New Era in Treatment
- Emergent BioSolutions Secures $400 Million Vaccine Orders for 2024
- Vicinity Motor Corp. Faces Financial Challenges Yet Shows Growth
- Morgan Stanley Lowers Rivian Stock Outlook and Insights
- Baird Reaffirms Cautious Stance on Amgen Amid Market Developments
- Mortgage Rates Decline: Homeowners Embrace Refinancing Boom
- Foreign Smartphone Sales Decline Significantly in August 2023
- Genespire Secures €46.6 Million to Propel Pediatric Gene Therapy
- Forecast for High Voltage Switchgear Market Growth and Trends
- Exploring Growth Potential in the Thermoplastic Polyurethane Market
- The Rise of Mycoplasma Testing: Future Growth and Trends
- Future Growth of Electronic Trial Master File Market Explained
- Octopus AIM VCT Unveils Latest Net Asset Value Insights
- Octopus AIM VCT 2 plc Announces Current Net Asset Value Insights
- IDEX Biometrics Launches New Share Issue to Enhance Growth
- Kymera Therapeutics Unveils Promising KT-621 Data for Allergies
- Steakholder Foods Partners with Bondor for Plant-Based Seafood
- Eightco's Strategic Vision: $100 Million Revenue Goal for 2025